Cartesian Therapeutics (RNAC) announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will succeed Carrie Cox, who is stepping down to focus on other responsibilities, including her recent appointment as Executive Chair of another publicly-traded company. In connection with Dr. Brunn’s assumption of the role of Chairman of the Board, Patrick Zenner, M.B.A., was named as Lead Independent Director of the Board.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics’ Descartes-08: A Promising Phase 3 Trial for Myasthenia Gravis
- Cartesian Therapeutics Advances Autoimmune Disorder Treatment with Descartes-08 Study
- Cartesian Therapeutics Advances SLE Treatment with Descartes-08 Study
- Cartesian Therapeutics Eliminates Chief Scientific Officer Role
- Cartesian Therapeutics Appoints New Chief Accounting Officer